CompletedPhase 2NCT02484664

COLA: A Pilot Clinical Trial of COX-2 Inhibition in LAM and TSC

Studying Lymphangioleiomyomatosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Brigham and Women's Hospital
Principal Investigator
David J Kwiatkowski, MD PhD
Brigham and Women's Hospital
Intervention
Celecoxib(drug)
Enrollment
12 enrolled
Eligibility
18-70 years · FEMALE
Timeline
20162018

Study locations (1)

Collaborators

National Heart, Lung, and Blood Institute (NHLBI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02484664 on ClinicalTrials.gov

Other trials for Lymphangioleiomyomatosis

Additional recruiting or active studies for the same condition.

See all trials for Lymphangioleiomyomatosis

← Back to all trials